• EMA’s CHMP backs six new products in January
  • Innate Pharma to Participate in the Kempen Life Sciences Conference
  • The evolving BTK story in multiple sclerosis: Clinical Report
  • Diagonal banks another $125M for ‘clustering’ antibody drugs
  • Pipeline cuts for Sanofi; Breakthru Medicine raises $60M
  • Burnout common but regrets are not in allergy, immunology
  • Sanofi’s venglustat succeeds in Phase 3 Gaucher trial but fails separate study in Fabry disease
  • Sanofi extends $180M to California T cell engager startup Kali
  • FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
  • Ocugen shares fall, despite positive eye disorder trial
  • Bipartisan INSULIN Act Targets $35 Monthly Cap for Private‑Insurance Users
  • SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
  • Amgen adds AML candidate in deal for U.K.-based Dark Blue: Deals Report
  • ‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s 'Anti-Science' Vaccine Policies
  • PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
  • Bipartisan INSULIN Act Targets $35 Monthly Cap for Private‑Insurance Users
  • WEF highlights 32 AI case studies with real-world business impact
  • Proteasomes: A Novel Approach to Target the Immune System
  • JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
  • TrumpRx Delayed Amid Potential Anti-Kickback Concerns
  • FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report
  • BrightInsight Secures $13M Funding Round
  • Facing Talent Crunch, Radiopharma Field Casts a Wide Net
  • Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China
  • QuantHealth Achieves 8x Financial Growth Across Life Sciences Engagements
  • Call goes out for type 1 diabetes screening in UK
  • Mixed data mars Sanofi's venglustat programme
  • 5 questions facing biopharma in 2026
  • ABB showcases the future of lab automation at SLAS 2026
  • Zip Launches Enterprise Transformation Office, Tapping Former Fortune 500 CPOs to Guide Procurement Leaders Through AI-Era Change
  • Enable Injections Scoops Up $30M
  • Lifordi Immunotherapeutics Inks New Funding
  • Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
  • Bipartisan INSULIN Act Seeks $35 Monthly Cap for Privately Insured Patients
  • The New Gold Rush in Brain Science
  • Ongoing Regulatory Uncertainty Means Innovation Is Now Higher Risk
  • Sanofi Moves Away From mRNA Flu Vaccine as CEO Projects Confidence
  • Boehringer signs €1bn+ deal for Simcere IBD candidate
  • Sanofi expects vaccine sales growth to dip amid ‘challenging environment’
  • 2025 Novel Large Molecule FDA Drug Approvals
  • Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
  • Sanofi adds HBV vaccine, shingles candidate via Dynavax takeout: Deals Report
  • #ACTRIMS26: Sanofi unpacks data from a failed Phase 3 tolebrutinib trial in PPMS
  • Best France ETFs for CAC 40 Exposure
  • Regulatory actions for April 1, 2026
  • Proxima Raises $80M in Seed Funding
  • Gut microbe may be linked to lupus pathogenesis
  • Takeda is ‘not in favor’ of Trump’s MFN deals, CEO-designate says
  • Momentum builds for local drug production
  • Sanofi plans amlitelimab dermatitis filing after new readout
  • Enable Injections Secures $30M Corporate Investment from Sanofi
  • Alveus Therapeutics Secures $37M Series A Extension Funding
  • Electra Therapeutics Raises $183M Series C to Fund Pivotal Rare Disease Trial
  • Sanofi invests $180M in T-cell engager startup Kali
  • Electra Therapeutics raises $183M in Series C led by Nextech and EQT Life Sciences
Sanofi - Latest News and Investment Deals
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Tuesday recap

Top Publishers

Top Creators

  • Ryan Allis

    Ryan Allis

    209 followers

  • Elon Musk

    Elon Musk

    80 followers

  • Sam Altman

    Sam Altman

    68 followers

  • Mark Cuban

    Mark Cuban

    57 followers

  • Jack Dorsey

    Jack Dorsey

    40 followers

See More →

Top Companies

  • SaasRise

    SaasRise

    211 followers

  • Anthropic

    Anthropic

    40 followers

  • OpenAI

    OpenAI

    22 followers

  • Hugging Face

    Hugging Face

    15 followers

  • xAI

    xAI

    12 followers

See More →

Top Investors

  • Andreessen Horowitz

    Andreessen Horowitz

    16 followers

  • Y Combinator

    Y Combinator

    15 followers

  • Sequoia Capital

    Sequoia Capital

    12 followers

  • General Catalyst

    General Catalyst

    8 followers

  • A16Z Crypto

    A16Z Crypto

    5 followers

See More →
NewsDealsSocialBlogsVideosPodcasts
HomeSanofi
Sanofi logo

Sanofi

0 followers

About Sanofi

Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients' daily life, wherever they live and enable them to enjoy a healthier life.

Recent News

EMA’s CHMP Backs Six New Products in January

Innate Pharma to Participate in the Kempen Life Sciences Conference

The Evolving BTK Story in Multiple Sclerosis: Clinical Report

Diagonal Banks Another $125M for ‘Clustering’ Antibody Drugs

Pipeline Cuts for Sanofi; Breakthru Medicine Raises $60M

Burnout Common but Regrets Are Not in Allergy, Immunology

Sanofi’s Venglustat Succeeds in Phase 3 Gaucher Trial but Fails Separate Study in Fabry Disease

Sanofi Extends $180M to California T Cell Engager Startup Kali

FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain

Ocugen Shares Fall, Despite Positive Eye Disorder Trial

Bipartisan INSULIN Act Targets $35 Monthly Cap for Private‑Insurance Users

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

Amgen Adds AML Candidate in Deal for U.K.-based Dark Blue: Deals Report

‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s 'Anti-Science' Vaccine Policies

PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026

Bipartisan INSULIN Act Targets $35 Monthly Cap for Private‑Insurance Users

WEF Highlights 32 AI Case Studies with Real-World Business Impact

Proteasomes: A Novel Approach to Target the Immune System

JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return

TrumpRx Delayed Amid Potential Anti-Kickback Concerns

FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report

BrightInsight Secures $13M Funding Round

Facing Talent Crunch, Radiopharma Field Casts a Wide Net

Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China

QuantHealth Achieves 8x Financial Growth Across Life Sciences Engagements

Call Goes Out for Type 1 Diabetes Screening in UK

Mixed Data Mars Sanofi's Venglustat Programme

5 Questions Facing Biopharma in 2026

ABB Showcases the Future of Lab Automation at SLAS 2026

Zip Launches Enterprise Transformation Office, Tapping Former Fortune 500 CPOs to Guide Procurement Leaders Through AI-Era Change

Enable Injections Scoops Up $30M

Lifordi Immunotherapeutics Inks New Funding

Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial

Bipartisan INSULIN Act Seeks $35 Monthly Cap for Privately Insured Patients

The New Gold Rush in Brain Science

Ongoing Regulatory Uncertainty Means Innovation Is Now Higher Risk

Sanofi Moves Away From mRNA Flu Vaccine as CEO Projects Confidence

Boehringer Signs €1bn+ Deal for Simcere IBD Candidate

Sanofi Expects Vaccine Sales Growth to Dip Amid ‘Challenging Environment’

2025 Novel Large Molecule FDA Drug Approvals

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Sanofi Adds HBV Vaccine, Shingles Candidate via Dynavax Takeout: Deals Report

#ACTRIMS26: Sanofi Unpacks Data From a Failed Phase 3 Tolebrutinib Trial in PPMS

Best France ETFs for CAC 40 Exposure

Regulatory Actions for April 1, 2026

Proxima Raises $80M in Seed Funding

Gut Microbe May Be Linked to Lupus Pathogenesis

Takeda Is ‘Not in Favor’ of Trump’s MFN Deals, CEO-Designate Says

Momentum Builds for Local Drug Production

Sanofi Plans Amlitelimab Dermatitis Filing After New Readout

Recent Deals

Enable Injections Secures $30M Corporate Investment From Sanofi

January 6, 2026

Alveus Therapeutics Secures $37M Series A Extension Funding

March 2, 2026

Electra Therapeutics Raises $183M Series C to Fund Pivotal Rare Disease Trial

October 27, 2025

Sanofi Invests $180M in T-Cell Engager Startup Kali

March 23, 2026

Electra Therapeutics Raises $183M in Series C Led by Nextech and EQT Life Sciences

October 22, 2025

Key Team Members

Brian Foard

Executive Vice President, Head of Specialty Care

Paul Hudson

Chief Executive Officer

François Roger

Executive Vice President, Chief Financial Officer

Natalie Bickford

Executive Vice President, Chief People Officer

Madeleine Roach

Executive Vice President, Business Operations

Key Facts

HQ Location

Paris, France

Founded

1994

Employees

10,000+

Status

Investor

Investor Type

Corporate Investor

Website

https://sanofi.com